849833-56-3

Usage

Uses

Used in Chemical Manufacturing:
N'-HYDROXY-2-METHYLPROPANIMIDAMIDE is used as a metal chelator for removing metal ions from solutions. This application is particularly beneficial in chemical manufacturing processes where the removal of metal contaminants is essential for product purity and quality.
Used in Water Treatment:
In the water treatment industry, N'-HYDROXY-2-METHYLPROPANIMIDAMIDE is used as a metal chelator to purify water by sequestering metal ions. This contributes to the overall safety and cleanliness of the water supply.
Used in Medical Applications:
N'-HYDROXY-2-METHYLPROPANIMIDAMIDE is used as a chelating agent for treating metal toxicity in the body. Its ability to bind with metal ions aids in the detoxification process, providing a potential therapeutic intervention for heavy metal poisoning.
Used as a Pharmaceutical Intermediate:
In the pharmaceutical industry, N'-HYDROXY-2-METHYLPROPANIMIDAMIDE serves as an intermediate in the synthesis of other compounds. Its role in the production of various medications highlights its importance in drug development and manufacturing.

Upstream product

• 78-82-0 Isobutyronitrile 

Downstream Products

• 1001398-17-9 4-({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}oxy)-1-[4-(methylsulfonyl)phenyl]-2,3-dihydro-1H-indole 
• 1199-49-1 3-isopropyl-5-(trichloromethyl)-1,2,4-oxadiazole 
• 1588943-57-0 3-isopropyl-5-(4-((1R,2S)-2-((4-(methylsulfonyl)benzyloxy)methyl)cyclopropyl)piperidin-1-yl)-1,2,4-oxadiazole 
• 163719-70-8 Ethyl 3-isopropyl-1,2,4-oxadiazole-5-carboxylate 
• 1415835-33-4 N-cyclopropyl-N-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-4-yl]-6-(4-methanesulfonyl-phenyl)-nicotinamide 
• 1391081-19-8 1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-4-[5-(4-methanesulfonyl-phenyl)-2,3-dihydro-benzofuran-2-yl]-piperidine 
• 1309377-33-0 C₂₄H₂₄F₂N₆O₃ 
• 1229419-06-0 2-phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid {4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-phenyl}-amide 
• 1035040-82-4 4-[(4-Chlorophenyl)methyl]-2-[((2R)-1-{2-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]ethyl}-2-pyrrolidinyl)methyl]-1(2H)-phthalazinone, hydrochloride 
• 1196486-71-1 4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-cyclohexanone 
• 1163126-27-9 2-ethyl-N-(3-fluoro-4-(4-((3-isopropyl-[1,2,4]oxadiazol-5-yl)(phenyl)methyl)piperazin-1-yl)phenyl)butyramide 
• 1037793-31-9 1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-4-[4-(4-tetrazol-1-ylphenoxymethyl)thiazol-2-yl]piperidine 
• 35613-84-4 isobutyramide oxime 

Relevant academic research and scientific papers

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease(AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5- containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age- Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer' s Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson' s disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.

COMPOUND HAVING GPR119 AGONISTIC ACTIVITY, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AS EFFECTIVE COMPONENT

The present invention relates to a novel compound having a GPR1 19 agonistic activity, a method for preparing the same, and a pharmaceutical composition including the same as an effective component. The present invention has an effective hypoglycemic acti

NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present invention relates to compounds of general formula I, wherein R1, LP, HetAr, Ar, and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

SUBSTITUTED PIPERIDINES AS GPR119 MODULATORS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention relates to compounds of general formula (I), wherein R1, Lp, HetAr, Ar, and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

PROCESS FOR THE PREPARATION OF OXADIAZOLES

Process for the preparation of oxadiazoles, useful as intermediates in the preparation of biologically active molecules.

BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS

The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

GPR119 Receptor Agonists

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.